Evidence map›Paper›PMID 36555568›Full record

ArticleInternational journal of molecular sciences2022

Antipsychotic- and Anxiolytic-like Properties of a Multimodal Compound JJGW08 in Rodents.

Elżbieta Żmudzka, Klaudia Lustyk, Monika Głuch-Lutwin, Barbara Mordyl, Alicja Zakrzewska-Sito, Paweł Mierzejewski, Jolanta Jaśkowska, Marcin Kołaczkowski, Jacek Sapa, Karolina Pytka

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Molecular Research on Mental Disorders.International journal of molecular sciences · 2023
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Elżbieta ŻmudzkaDepartment of Social Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
Klaudia LustykDepartment of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
Monika Głuch-LutwinDepartment of Pharmacobiology, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
Barbara MordylDepartment of Pharmacobiology, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
Alicja Zakrzewska-SitoDepartment of Pharmacology, Institute of Psychiatry and Neurology, Sobieskiego 9, 02-957 Warszawa, Poland.
Paweł MierzejewskiDepartment of Pharmacology, Institute of Psychiatry and Neurology, Sobieskiego 9, 02-957 Warszawa, Poland.
Jolanta JaśkowskaDepartment of Organic Chemistry and Technology, Faculty of Chemical and Engineering and Technology, Cracow University of Technology, Warszawska 24, 31-155 Krakow, Poland.
Marcin KołaczkowskiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
Jacek SapaDepartment of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.
Karolina PytkaDepartment of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.ORCID 0000-0001-7134-9515
Jagiellonian University · PLInstitute of Psychiatry and Neurology · PLCracow University of Technology · PL

Funding

Jagiellonian University K/ZDS/007133Jagiellonian University N42/DBS/000142
6 · The paper itself

Abstract

Schizophrenia is a chronic mental illness, which remains difficult to treat. A high resistance to the available therapies, their insufficient efficacy, and numerous side effects are the reasons why there is an urgent need to develop new antipsychotics. This study aimed to assess the antipsychotic-like effects of JJGW08, a novel arylpiperazine alkyl derivative of salicylamide, in rodents. First, considering the JJGW08 receptor profile, we investigated the compound's intrinsic activity towards dopamine D

Indexed as

Anti-Anxiety AgentsAntipsychotic AgentsAmphetamineAnimalsCatalepsyDizocilpine MaleateDopamineMiceRatsRodentiaSerotoninAmphetamineAnti-Anxiety AgentsAntipsychotic AgentsDizocilpine MaleateDopamineSerotonin5-HT1A receptor antagonistantipsychotic-like activityanxiolytic-like effectarylpiperazine derivative of salicylamideD2 receptor antagonist

Identifiers

PMID36555568
PMCPMC9781916
OpenAlexW4311511044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.